According to filings with the U.S. Securities and Exchange Commission, Bright Uro, Inc. is raising up to $14,878,400.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Bright Uro, Inc.
Bright Uros mission is to revolutionize lower urinary tract symptoms (LUTS) care by building the next generation of diagnostic devices for Urology. We developed our Glean Urodynamics System to disrupt outdated urodynamics approaches with wireless, catheter-free monitoring designed to improve patient comfort and optimize clinical outcomes. Utilizing advanced hardware, software, and data science, our goal is to develop the most accurate, comfortable, and efficient tools possible to unlock new data streams and offer actionable insight for clinicians.

To learn more about Bright Uro, Inc., visit http://www.gleanuds.com/
Bright Uro, Inc. Linkedin Page: https://www.linkedin.com/company/brighturo/

Contact:
Derek Herrera, Chief Executive Officer
949-590-0555
https://www.linkedin.com/in/derekherrera/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.